News

Help for Today and Hope for Tomorrow: Empowering the CMT Community at the 2024 CMTA Patient & Research Summit in Denver The 2024 CMTA Patient & Research Summit in Colorado was a remarkable gathering of more than 450 attendees—both in person ...

The Charcot-Marie-Tooth Association (CMTA) continues its mission to accelerate research that impacts the lives of those living with Charcot-Marie-Tooth disease (CMT) and is excited to share progress in a CRISPR research project focused on developing gene editing strategies for CMT1A ...

CMT2S: A Potential New Treatment on the Horizon Charcot-Marie-Tooth Disease Type 2S (CMT2S) is a severe axonal type of CMT caused by certain autosomal recessive mutations of the IGHMBP2 gene. CMTA-STAR Alliance Partner Vanda Pharmaceuticals recently received USFDA approval for ...

The Charcot-Marie-Tooth Association (CMTA) continues its mission to accelerate research that impacts the lives of those living with Charcot-Marie-Tooth disease (CMT). Building on previous successes, CMTA announced earlier this year a strategic $450,000 investment in a new research project to ...

THE CHARCOT-MARIE-TOOTH ASSOCIATION SUPPORTS THE ACCELERATING KIDS’ ACCESS TO CARE ACT (H.R.4758 / S.2372) The Accelerating Kids’ Access to Care Act (H.R.4758 / S.2372) is a bipartisan bill that aims to simplify the Medicaid enrollment process, allowing out-of-state providers to remain ...